<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular diseases</z:e> are the primary cause of mortality in France </plain></SENT>
<SENT sid="1" pm="."><plain>Many epidemiological studies have shown that the total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration is a risk indicator for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, it has been shown that the <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration can be effectively lowered by supplementation with <z:chebi fb="9" ids="27470">folic acid</z:chebi>, <z:chebi fb="14" ids="27306">vitamin B6</z:chebi> and <z:chebi fb="13" ids="33611">B12</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>However, it is not yet known whether a reduction of the <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration by such a supplementation indeed leads to a decreased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Another possible dietary factor that may lower the risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> is fish-oil, which is rich in <z:chebi fb="6" ids="25681">omega-3 fatty acids</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>These fatty acids lower platelet aggregation and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and may have antiarrhythmic effects </plain></SENT>
<SENT sid="6" pm="."><plain>Some trials have investigated the effect of fish or fish-oil on cardiovascular mortality, and the results, although not conclusive, suggest a protective effect of a higher intake </plain></SENT>
<SENT sid="7" pm="."><plain>In the SU.FOL.OM3 study we will evaluate the effect of supplementation at nutritional doses of <z:chebi fb="3" ids="37445">folate</z:chebi> (in the natural 5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="0" ids="20506,26907">tetrahydrofolate</z:chebi> form) in combination with <z:chebi fb="14" ids="27306">vitamin B6</z:chebi> and <z:chebi fb="13" ids="33611">B12</z:chebi> and/or <z:chebi fb="6" ids="25681">omega-3 fatty acids</z:chebi> and/or placebo on recurrent ischemic diseases in a factorial design </plain></SENT>
<SENT sid="8" pm="."><plain>The supplements will be randomly allocated to the participants in a double-blind fashion </plain></SENT>
<SENT sid="9" pm="."><plain>In total 3,000 patients aged between 45 and 80 years who had a past history of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or unstable <z:hpo ids='HP_0001681'>angina pectoris</z:hpo> or an <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> will be included </plain></SENT>
<SENT sid="10" pm="."><plain>The participants will be supplemented and followed up for a period of five years </plain></SENT>
</text></document>